Royalty Pharma Analyst Ratings
Royalty Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 71.05% | Morgan Stanley | $52 → $53 | Maintains | Overweight |
| 07/11/2023 | 67.82% | Morgan Stanley | $52 → $52 | Reiterates | Overweight → Overweight |
| 05/10/2023 | 67.82% | Morgan Stanley | $50 → $52 | Maintains | Overweight |
| 04/10/2023 | 61.37% | Morgan Stanley | $48 → $50 | Maintains | Overweight |
| 04/06/2023 | 93.64% | Tigress Financial | $57 → $60 | Reiterates | → Buy |
| 02/16/2023 | 54.91% | UBS | $51 → $48 | Maintains | Buy |
| 12/06/2022 | 64.6% | Morgan Stanley | $54 → $51 | Maintains | Overweight |
| 11/09/2022 | 74.28% | Morgan Stanley | $51 → $54 | Maintains | Overweight |
| 10/18/2022 | 67.82% | JP Morgan | $50 → $52 | Maintains | Overweight |
| 08/08/2022 | 64.6% | Morgan Stanley | $48 → $51 | Maintains | Overweight |
| 07/14/2022 | 83.96% | Tigress Financial | $52 → $57 | Maintains | Buy |
| 06/14/2022 | 51.69% | UBS | → $47 | Initiates Coverage On | → Buy |
| 05/13/2022 | 71.05% | Scotiabank | → $53 | Initiates Coverage On | → Outperform |
| 04/27/2022 | 80.73% | Goldman Sachs | → $56 | Initiates Coverage On | → Buy |
| 04/14/2022 | 61.37% | JP Morgan | → $50 | Upgrades | Neutral → Overweight |
| 04/06/2022 | 54.91% | Morgan Stanley | $46 → $48 | Upgrades | Equal-Weight → Overweight |
| 10/29/2021 | 61.37% | Citigroup | → $50 | Upgrades | Neutral → Buy |
| 08/16/2021 | 48.46% | Morgan Stanley | $51 → $46 | Maintains | Equal-Weight |
| 07/30/2021 | 61.37% | Tigress Financial | → $50 | Initiates Coverage On | → Buy |
| 11/09/2020 | 64.6% | UBS | → $51 | Upgrades | Neutral → Buy |
| 07/13/2020 | 61.37% | JP Morgan | → $50 | Initiates Coverage On | → Neutral |
| 07/13/2020 | 77.51% | B of A Securities | → $55 | Initiates Coverage On | → Buy |
| 07/13/2020 | 64.6% | Morgan Stanley | → $51 | Initiates Coverage On | → Equal-Weight |
| 07/13/2020 | 77.51% | Cowen & Co. | → $55 | Initiates Coverage On | → Outperform |
| 07/13/2020 | 80.73% | SunTrust Robinson Humphrey | → $56 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/09/2023 | 71.05% | 摩根士丹利 | 52 美元 → 53 美元 | 维护 | 超重 |
| 07/11/2023 | 67.82% | 摩根士丹利 | 52 美元 → 52 美元 | 重申 | 超重 → 超重 |
| 05/10/2023 | 67.82% | 摩根士丹利 | 50 美元 → 52 美元 | 维护 | 超重 |
| 2023 年 10 月 4 日 | 61.37% | 摩根士丹利 | 48 美元 → 50 美元 | 维护 | 超重 |
| 04/06/2023 | 93.64% | 泰格雷斯金融 | 57 美元 → 60 美元 | 重申 | → 购买 |
| 02/16/2023 | 54.91% | 瑞银（UBS） | 51 美元 → 48 美元 | 维护 | 购买 |
| 12/06/2022 | 64.6% | 摩根士丹利 | 54 美元 → 51 美元 | 维护 | 超重 |
| 11/09/2022 | 74.28% | 摩根士丹利 | 51 美元 → 54 美元 | 维护 | 超重 |
| 2022 年 10 月 18 日 | 67.82% | 摩根大通 | 50 美元 → 52 美元 | 维护 | 超重 |
| 08/08/2022 | 64.6% | 摩根士丹利 | 48 美元 → 51 美元 | 维护 | 超重 |
| 07/14/2022 | 83.96% | 泰格雷斯金融 | 52 美元 → 57 美元 | 维护 | 购买 |
| 06/14/2022 | 51.69% | 瑞银（UBS） | → 47 美元 | 启动覆盖开启 | → 购买 |
| 05/13/2022 | 71.05% | 丰业银行 | → 53 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 04/27/2022 | 80.73% | 高盛 | → 56 美元 | 启动覆盖开启 | → 购买 |
| 2022 年 4 月 14 日 | 61.37% | 摩根大通 | → 50 美元 | 升级 | 中性 → 超重 |
| 04/06/2022 | 54.91% | 摩根士丹利 | 46 美元 → 48 美元 | 升级 | 重量相等 → 超重 |
| 10/29/2021 | 61.37% | 花旗集团 | → 50 美元 | 升级 | 中性 → 买入 |
| 2021 年 8 月 16 日 | 48.46% | 摩根士丹利 | 51 美元 → 46 美元 | 维护 | 重量相等 |
| 07/30/2021 | 61.37% | 泰格雷斯金融 | → 50 美元 | 启动覆盖开启 | → 购买 |
| 2020 年 9 月 11 日 | 64.6% | 瑞银（UBS） | → 51 美元 | 升级 | 中性 → 买入 |
| 07/13/2020 | 61.37% | 摩根大通 | → 50 美元 | 启动覆盖开启 | → 中立 |
| 07/13/2020 | 77.51% | B of A 类证券 | → 55 美元 | 启动覆盖开启 | → 购买 |
| 07/13/2020 | 64.6% | 摩根士丹利 | → 51 美元 | 启动覆盖开启 | → 重量相等 |
| 07/13/2020 | 77.51% | Cowen & Co. | → 55 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 07/13/2020 | 80.73% | SunTrust 罗宾逊汉弗莱 | → 56 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Royalty Pharma (RPRX)?
Royalty Pharma（RPRX）的目标价格是多少？
The latest price target for Royalty Pharma (NASDAQ: RPRX) was reported by Morgan Stanley on August 9, 2023. The analyst firm set a price target for $53.00 expecting RPRX to rise to within 12 months (a possible 71.05% upside). 9 analyst firms have reported ratings in the last year.
摩根士丹利于2023年8月9日公布了Royalty Pharma（纳斯达克股票代码：RPRX）的最新目标股价。这家分析公司将目标股价定为53.00美元，预计RPRX将在12个月内升至53.00美元（可能上涨71.05％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Royalty Pharma (RPRX)?
Royalty Pharma（RPRX）的最新分析师评级是多少？
The latest analyst rating for Royalty Pharma (NASDAQ: RPRX) was provided by Morgan Stanley, and Royalty Pharma maintained their overweight rating.
Royalty Pharma（纳斯达克股票代码：RPRX）的最新分析师评级由摩根士丹利提供，Royalty Pharma维持其增持评级。
When is the next analyst rating going to be posted or updated for Royalty Pharma (RPRX)?
Royalty Pharma（RPRX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Royalty Pharma的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Royalty Pharma的最新评级是在2023年8月9日提交的，因此您应该预计下一个评级将在2024年8月9日左右公布。
Is the Analyst Rating Royalty Pharma (RPRX) correct?
分析师对Royalty Pharma（RPRX）的评级是否正确？
While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $52.00 to $53.00. The current price Royalty Pharma (RPRX) is trading at is $30.99, which is out of the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Royalty Pharma（RPRX）评级维持不变，目标股价为52.00美元至53.00美元。Royalty Pharma（RPRX）目前的交易价格为30.99美元，超出了分析师的预测区间。